nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

PURPOSE: Resistance to endocrine therapy poses a major clinical challenge for patients with hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC). We present the preplanned 24-month final overall survival (OS) results, alongside up...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamilton, Erika, Cortes, Javier, Ozyilkan, Ozgur, Chen, Shin-Cheh, Petrakova, Katarina, Manikhas, Aleksey, Jerusalem, Guy, Hegg, Roberto, Huober, Jens, Zhang, Wei, Chen, Yanyun, Martin, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338008/
https://www.ncbi.nlm.nih.gov/pubmed/35829935
http://dx.doi.org/10.1007/s10549-022-06662-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338008/
https://www.ncbi.nlm.nih.gov/pubmed/35829935
http://dx.doi.org/10.1007/s10549-022-06662-9

Ejemplares similares